Edition:
United Kingdom

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

5.12USD
23 Apr 2019
Change (% chg)

-- (--)
Prev Close
$5.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
719,366
52-wk High
$9.28
52-wk Low
$1.87

Summary

Name Age Since Current Position

John Melo

52 2008 President, Chief Executive Officer, Director

Kathleen Valiasek

2017 Chief Financial Officer

Joel Cherry

54 2011 President - Research and Development

Oreste Fieschi

2019 President of Sweeteners and Ingredients

Eduardo Alvarez

2017 Chief Operating Officer

Anthony Hughes

53 2018 Chief Accounting Officer

Philip Eykerman

51 2017 Director

Frank Kung

69 2017 Director

Steven Mills

63 2018 Director

Fernando Reinach

60 2008 Independent Director

Abdullah Bin Khalifa Al Thani

57 2012 Independent Director

Geoffrey Duyk

57 2012 Independent Director

Carole Piwnica

61 2009 Independent Director

Raymond Williams

64 2013 Independent Director

Peter DeNardo

2015 Director, Investor Relations and Corporate Communications

Biographies

Name Description

John Melo

Mr. John G. Melo is President, Chief Executive Officer, Director of Amyris, Inc. Mr. Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as our Chief Executive Officer and a director since January 2007 and as our President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum), one of the world’s largest energy firms, from 1997 to 2006, most recently as President of U.S. Fuels Operations from 2004 until December 2006, and previously as Chief Information Officer of the refining and marketing segment from 2001 to 2003, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, from 2000 to 2001, and Director of Global Brand Development from 1999 to 2000. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, from 1996 to 1997, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of Renmatix, Inc., and on the board of the Industrial action of Bio and also on the board of the California Life Sciences Association. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. Mr. Melo’s experience as a senior executive at one of the world’s largest energy companies provides critical leadership in shaping strategic direction and business transactions, and in building teams to drive innovation.

Kathleen Valiasek

Ms. Kathleen Valiasek serves as Chief Financial Officer of the Company. Ms. Valiasek served as Chief Executive Officer of a finance and strategic consulting firm she founded in 1994, in which capacity she provided financial and strategic consulting services to several companies. Ms. Valiasek's experience encompasses serving with fast-growing companies including those among the Fortune 500 and across the life sciences, tech, retail, telecommunications, real estate, and healthcare sectors. Prior to joining Amyris, Valiasek was Founder and Chief Executive Officer of Lenox Group, Inc., a finance and strategic consulting firm where she worked closely with the senior management teams of private and public companies including such organizations as Kaiser Permanente, Inc., Albertsons, Inc. and Cytokinetics, Inc. Prior to that, she served in key venture capital, real estate development and accounting roles. Ms. Valiasek results-driven background includes specific areas of expertise in finance, SEC reporting, strategic planning, debt and equity financing, business development, and mergers and acquisitions. Valiasek holds a Bachelor of Business Administration degree in accounting from the University of Massachusetts, Amherst, MA

Joel Cherry

Dr. Joel Cherry, Ph.D., is President - Research and Development of Amyris, Inc., since July 2011. Dr. Cherry previously served as Senior Vice President of Research Programs and Operations since November 2008. Before joining Amyris, Dr. Cherry was Senior Director of Bioenergy Biotechnology at Novozymes, a biotechnology company focusing on development and manufacture of industrial enzymes from 1992 to November 2008. At Novozymes, he served in a variety of R&D scientific and management positions, including membership in Novozymes’ International R&D Management team, and as Principal Investigator and Director of the BioEnergy Project, a U.S. Department of Energy-funded $18 million effort initiated in 2000. Dr. Cherry holds a Bachelor of Arts degree in Chemistry from Carleton College and a Doctor of Philosophy degree in Biochemistry from the University of New Hampshire.

Oreste Fieschi

Mr. Oreste Fieschi is President of Sweeteners and Ingredients of the company. Most recently, he led global sales and marketing as the Chief Commercial Officer for Naturex, a leader in natural ingredients recently bought by Givaudan. Mr. Oreste has over 20 years' experience in senior commercial roles in diverse markets including chemicals, personal care, and food & beverage, including six years leading the sales growth strategy for Tate & Lyle Latin America. Prior to that, he held key commercial and business development roles with such companies as IFF, a leading developer and manufacturer of flavors and fragrances. Mr. Oreste holds a Master's degree in Business Administration from the Business School São Paulo, BSP (in partnership with Toronto University), and several other education certifications in finance and accounting, marketing, and chemical engineering.

Eduardo Alvarez

Mr. Eduardo Alvarez is Chief Operating Officer of the company. Mr. Alvarez has over 30 years of global, multi-functional, operations experience both running and advising growth companies. Previously, he served as Global Operations Strategy Leader for PwC. During his tenure, he co-led the integration of his prior company, Booz & Company, following its acquisition by PwC. In his role, he grew operations into a global practice with $1.5 billion in revenue and 4,000 employees. His assignments focused on delivering structural cost improvements while also driving sustained revenue growth. His experience also includes roles at General Electric and AT&T. Alvarez holds a Master of Business Administration with honors from Harvard University, a Master of Science in Mechanical Engineering in computer control and manufacturing from the University of California, Berkeley, as well as a Bachelor of Science degree in mechanical engineering with high honors from the University of Michigan.

Anthony Hughes

Mr. Anthony Hughes is Chief Accounting Officer of the company. Mr. Hughes has served as Senior Vice President, Chief Accounting Officer of Service Source International, Inc., a publicly-traded provider of outsourced, performance-based business solutions, since May 2015, and previously served as the Vice President, Corporate Controller of CRC Health Group, a provider of behavioral health care services, from January 2013 to May 2015. Mr. Hughes holds Bachelor of Science and Master of Science degrees in Accounting from the University of North Texas.

Philip Eykerman

Mr. Philip Eykerman has been appointed as Director of the Company. Mr. Eykerman has served as the Executive Vice-President, Corporate Strategy & Acquisitions of Koninklijke DSM N.V. (together with its affiliates, “DSM”), an entity with which Amyris has a commercial and financial relationship and which is an owner of greater than five percent of the company’s outstanding common stock, since 2011. In this role, he is responsible for corporate and business group strategy development, budgeting and planning, improvement programs, and all M&A activities. In 2015, he was also appointed as a member of the DSM Executive Committee and at present is responsible for the Pharmaceuticals as well as DSM Food Specialties activities. Next to these roles within DSM, he is also a Supervisory Board member of DSM Sinochem Pharmaceuticals (DSM/Sinochem JV), and a Supervisory Board member of ChemicaInvest (DSM/CVC JV), and previously served as a member of the Supervisory Board of Patheon N.V. from March 2014 to August 2017. Before joining DSM, Mr. Eykerman worked for 14 years at McKinsey & Company of which the last 9 years as a Partner and leader of McKinsey’s Chemicals Practice in the Benelux and France. Mr. Eykerman holds a master degree in Chemical Engineering from the KU Leuven (Belgium) and in Refinery Engineering from the Institut Francais du Pétrole (France). Mr. Eykerman’s experience in corporate strategy, mergers and acquisitions and operations enables him to provide insight to the Board regarding potential new opportunities for Amyris.

Frank Kung

Dr. Frank F. C. Kung is Director of the company. Dr. Kung is a founding member of Vivo Capital LLC (“Vivo”), a healthcare focused investment firm founded in 1996 in Palo Alto, California, which is an owner of greater than five percent of the company’s outstanding common stock. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. Dr. Kung later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a Doctor of Philosophy degree in molecular biology and a Master of Business Administration degree from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies. Dr. Kung’s experience in healthcare and biotechnology and investing in companies enables him to provide the Board and management with guidance regarding the company’s business strategy and access to financial markets.

Steven Mills

Mr. Steven (Steve) R. Mills is Director of the Company. Mr. Mills has 40 years of experience in the fields of accounting, corporate finance, strategic planning, risk management, and mergers and acquisitions. He served as Chief Financial Officer of the Company from May 2012 to December 2013. Prior to joining the Company, Mr. Mills had a 33-year career at Archer-Daniels-Midland Company (“ADM”), one of the world’s largest agricultural processors and food ingredient providers. At ADM, he held various senior executive roles, including Chief Financial Officer, Controller, and head of Global Strategic Planning. Since 2013, Mr. Mills has served as a consultant and advisor to clients in the private equity, agribusiness, and financial services fields. Mr. Mills currently serves on the boards of Black Hills Corporation (where he also serves as the chair of the audit committee), Farmers Edge, Inc., Big Red Group Holdings, LLC, Illinois College (where he also serves as the chairman of the board), and First Illinois Corporation (along with its wholly-owned banking subsidiary, Hickory Point Bank & Trust). Mr. Mills holds a Bachelor of Science degree in Mathematics from Illinois College.

Fernando Reinach

Dr. Fernando de Castro Reinach, Ph.D., is Independent Director of Amyris, Inc. Dr. Reinach has been a managing partner of Pitanga Fund, a venture capital fund based in Brazil, since May 2011. From 2001 to May 2010, Dr. Reinach was a general partner at Votorantim Novos Negócios Ltda. Before joining Votorantim, he was involved in the creation of two companies, Genomic Engenharia Molecular Ltda., a molecular diagnostic laboratory, and .ComDominio S/A, a datacenter company. Dr. Reinach holds a Bachelor of Science degree in biology from the University of São Paulo and a Doctor of Philosophy degree in Cell and Molecular Biology from Cornell University Medical College. Dr. Reinach’s experience with Brazilian business practices enables him to provide important insight and guidance to our management team and Board and to assist management with establishing and developing operations in Brazil.

Abdullah Bin Khalifa Al Thani

H. H. Sheikh Abdullah Bin Khalifa Al Thani is an Independent Director of Amyris, Inc., since March 15, 2012. HH has served as Special Advisor to the Emir of Qatar since his appointment in April 2007, and was Prime Minister of Qatar from October 1996 to April 2007. HH has served as chairman of the board of directors of Qatar Investment and Projects Development Holding Company, a Qatari investment group, since March 2011 and as chairman of the board of directors of Specialized International Services (SIS) Qatar, a business investment company, since October 2011. HH graduated from the Royal Military Academy Sandhurst. HH brings to the Board and our management team extensive experience in project development and investment, and his international stature and resources provide us with potential additional opportunities to build and finance our business.

Geoffrey Duyk

Dr. Geoffrey M. Duyk, M.D., Ph.D., is an Independent Director of Amyris, Inc., effective May 3, 2012. Dr. Duyk previously served on the Board from May 2006 to May 2011. Dr. Duyk is a partner of Circularis Partners LP. Previously, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies (together with its affiliates, “TPG”) from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Elevance Renewable Sciences; Inocucor Technologies, Inc.; and reGen Holdings Limited as well as on the non-profit Case Western Reserve University Board of Trustees and The American Society of Human Genetics board of directors. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. Dr. Duyk serves as a member of Scientific Advisory Boards for Bayer CropSciences, HudsonAlpha, and Lawrence Berkeley National Laboratory (DOE). The Wesleyan University Board of Trustees from 2008 to June 2014, Aerie Pharmaceuticals from August 2005 to June 2017, and DNAnexus, Inc. from 2011 to 2017. Dr. Duyk is currently a Board Observer of Anuvia Planet Nutrients; DNAnexus and Genomatica. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and Doctor of Philosophy and Medicine degrees from Case Western Reserve University. Dr. Duyk’s experience with the biotechnology industry enables him to provide insight and guidance to our management team and Board.

Carole Piwnica

Ms. Carole Piwnica Ph.D., is an Independent Director of Amyris, Inc., since September 2009. Ms. Piwnica has been Director of NAXOS UK, a consulting firm advising private equity, since January 2008. Previously, Ms. Piwnica served as a director, from 1996 to 2006, and Vice-Chairman of Governmental Affairs, from 2000 to 2006, of Tate & Lyle Plc, a European food and agricultural ingredients company. Ms. Piwnica was a chairman of Amylum Group, a European food ingredient company and affiliate of Tate & Lyle Plc, from 1996 to 2000. Ms. Piwnica was a member of the board of directors of Aviva plc, a British insurance company, from May 2003 to December 2011, a member of the Biotech Advisory Council of Monsanto from May 2006 to October 2009, a member of the board of directors of Dairy Crest from 2007 until 2010, a member of the board of directors of Toepfer Gmbh from 1996 until 2010 and a member of the board of directors of Louis Delhaize (retail, Belgium) from 2010 until 2013. In 2010, Ms. Piwnica was appointed as a member of the boards of Eutelsat (satellites, France) and Sanofi (pharmaceuticals, France). In 2014, she was appointed as a member of the board of Rothschild (financial services, France). Ms. Piwnica holds a Law degree from the Université Libre de Bruxelles and a Master of Laws degree from New York University. Ms. Piwnica has also been a member of the bar association of the state of New York, USA since 1985 and was a member of the bar association of Paris, France from 1988 until 2013. Based on her multinational corporate leadership experience and extensive legal and corporate governance experience, Ms. Piwnica contributes guidance to the management team and the Board in leadership of multinational agricultural processing businesses and on legal and corporate governance obligations and best practices.

Raymond Williams

Mr. Raymond Neil Williams is an Independent Director of Amyris, Inc., effective May 9, 2013. Mr. Williams served as Executive Vice President and Chief Financial Officer of Intuit Inc. from January 2008 through January 2018. In such position he was responsible for all financial aspects of Intuit, including corporate strategy and business development, investor relations, financial operations and real estate. Before joining Intuit, Mr. Williams was the Executive Vice President and Chief Financial Officer for Visa U.S.A., Inc. In that role, he led all financial functions for Visa U.S.A., Inc. and its subsidiaries, including financial planning, business planning and financial monitoring. Mr. Williams concurrently served as Chief Financial Officer for Inovant LLC, Visa’s global information technology organization, responsible for global transactions processing and technology development. His previous banking experience includes senior financial positions at commercial banks in the Southern and Midwest regions of the United States. Since March 2012, Mr. Williams has also served as a board member and chair of the audit committee of RingCentral, Inc. Mr. Williams joined the board and audit committee of Oportun, Inc. in November 2017. Mr. Williams is a certified public accountant and received his Bachelor’s degree in business administration from the University of Southern Mississippi. Mr. Williams’ expertise in accounting, finance and management enables him to provide important insight and guidance to our management team and Board and to serve as chair of our Audit Committee.

Peter DeNardo